The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Subscribe To Our Newsletter & Stay Updated
